de Matos Veronica S, do Nascimento Ana L R, Pereira Priscila G, Rabelo Kíssila, Andrade Cherley B V, Moraes Alan C N, Salata Camila, Araújo Victor H V de O, Ciambarella Bianca Torres, Bonfim Vieira Aline, Alves Luciana Lontro, da Silva Jemima F R, de Carvalho Jorge J
Laboratory of Ultrastructure and Tecidual Biology, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Translational Endocrinology Laboratory, Institute of Biophysics Carlos Chagas Filho, Health Sciences Center, UFRJ, Rio de Janeiro, Brazil.
Int J Hypertens. 2020 Oct 21;2020:7684849. doi: 10.1155/2020/7684849. eCollection 2020.
Hypertension is a disease classified as primary or secondary, manifested not only by elevation of blood pressure but also involved in structural and functional changes of target organs. Renal artery stenosis is a leading factor of secondary hypertension, and its progress is associated with overactivation of the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a renin inhibiting drug that suppresses RAAS and culminates in decreased renin release, plasma angiotensin II concentration, and inhibition of aldosterone secretion. In this sense, the aim of the present study was to analyze the structural and ultrastructural morphophysiology of the adrenal glomerular zone, after treatment with aliskiren in Wistar rats with 2K1C hypertension. Parameters as structure and ultrastructure of the adrenal glomerular zone, cellular apoptosis, nuclear cell proliferation, and AT1 receptor expression were analyzed by immunostaining and electron microscopy. Our results showed that the hypertensive animals treated with aliskiren presented a reestablishment of AT1 receptor expression and decrease in apoptosis and autophagy. In addition, treatment with aliskiren improves the cell aspects in the adrenal glomerular zone, evidenced by ultrastructural analysis through preserved nuclei and well-developed mitochondria. Therefore, our evidence suggests that aliskiren has a beneficial effect on the adrenal glomerular zone remodeling in animals with renovascular hypertension.
高血压是一种分为原发性或继发性的疾病,不仅表现为血压升高,还涉及靶器官的结构和功能变化。肾动脉狭窄是继发性高血压的主要因素,其进展与肾素-血管紧张素-醛固酮系统(RAAS)的过度激活有关。阿利吉仑是一种肾素抑制药物,可抑制RAAS,最终导致肾素释放减少、血浆血管紧张素II浓度降低以及醛固酮分泌受到抑制。从这个意义上讲,本研究的目的是分析用阿利吉仑治疗2K1C高血压Wistar大鼠后肾上腺球状带的结构和超微结构形态生理学。通过免疫染色和电子显微镜分析肾上腺球状带的结构和超微结构、细胞凋亡、细胞核细胞增殖以及AT1受体表达等参数。我们的结果表明,用阿利吉仑治疗的高血压动物呈现出AT1受体表达的重建以及凋亡和自噬的减少。此外,阿利吉仑治疗改善了肾上腺球状带的细胞状况,通过保存的细胞核和发育良好的线粒体进行超微结构分析证明了这一点。因此,我们的证据表明,阿利吉仑对肾血管性高血压动物的肾上腺球状带重塑具有有益作用。